

ACTIVE CLINICAL TRIALS

Protocol Number	Title
VICC GI 0804 – Open to Accrual Industry – Pfizer	Randomized, Phase II Study of Folfox or Folfiri with AG-013736 Or Bevacizumab in Patients with Metastatic Colorectal Cancer After Failure of an Irinotecan or Oxaliplatin-Containing First-Line Regimen
VICC GI 0815 PI – Jordan Berlin, MD	A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer.
VICC GI 0837 Industry – AstraZeneca	A Randomized, Double-Blind, Multicenter, Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) In Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer. (Horizon III Trial)
VICC HN 0582 – Open to Accrual PI – Jill Gilbert, MD	A Phase II Trial: Efficacy and Toxicity of Induction Pemetrexed (ALIMTA) and Oxaliplatin (ELOXATIN) in Patients with Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
VICC HN 0585 – Open to Accrual Industry – ImClone	Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma
VICC SUPP 0424 – Open to Accrual PI – Nancy Wells, DNSc	Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients with Cancer-Related Pain
VICC THO 0632 PI – Thomas Stinchcombe, MD	Phase II Trial of Abraxane and Carboplatin in Extensive Stage Small Cell Lung Cancer
VICC THO 0746 – Open to Accrual PI – Alan Sandler, MD	A phase I/II study of nab-paclitaxel and carboplatin with concurrent radiation therapy for unresectable stage III non-small-cell lung cancer (NSCLC)
VICC URO 0852 Industry – Pfizer	Axitinib (AG-013736) As Second-Line Therapy for Metastatic RCC: Axis Trial (A4061032)

PENDING CLINICAL TRIALS

Protocol Number	Title
VICC GI 0844 Industry – Amgen	A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer (20060447)
VICC THO 0772 PI – Bo Lu, MD	A Phase I/II Study of RAD001 and Radiation Therapy in Patients with Brain Metastasis from Non-small Cell Lung Cancer (NSCLC)
VICC THO 0830 Industry – Pfizer	Randomized, Open Label, Phase III Trial of CP-751,871 in Combination with Paclitaxel and Carboplatin Vs. Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer (A4021016)
VICC THO 0833 Industry – Pfizer	Randomized Phase II Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Patients with Advanced NSCLC (A4061030)
VICC URO 0851 Industry – Pfizer	A Multicenter, Randomized, Double-Blind, Phase 3 Study of Sunitinib plus Prednisone versus Prednisone in Patients with Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure of a Docetaxel-Based Chemotherapy Regimen (A6181120)